Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family...